Stockscreener 앱 받기
10.44
0.69%
0.0638
전일 마감가:
$10.38
열려 있는:
$10.45
하루 거래량:
315.51K
Relative Volume:
0.37
시가총액:
$650.49M
수익:
$202.09M
순이익/손실:
$-61.69M
주가수익비율:
-9.6702
EPS:
-1.08
순현금흐름:
$-35.64M
1주 성능:
+2.16%
1개월 성능:
-19.79%
6개월 성능:
-34.84%
1년 성능:
-10.82%
1일 변동 폭
$10.36
$10.73
1주일 범위
$9.82
$10.97
52주 변동 폭
$8.67
$17.82
Evolus Inc Stock (EOLS) Company Profile
명칭
Evolus Inc
전화
(949) 284-4555
주소
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
EOLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
10.45 | 650.49M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
149.81 | 66.56B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.46 | 45.61B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.31 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.96 | 15.25B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
292.21 | 12.79B | 2.76B | 1.11B | 898.10M | 22.77 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | BTIG Research | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 개시 | Needham | Buy |
| 2022-05-12 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-04-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-24 | 다운그레이드 | Truist | Buy → Hold |
| 2020-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-02-06 | 재개 | Mizuho | Buy |
| 2019-11-26 | 개시 | SVB Leerink | Outperform |
| 2019-09-05 | 재개 | Mizuho | Buy |
| 2019-06-28 | 개시 | Wells Fargo | Market Perform |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2019-01-29 | 개시 | Stifel | Buy |
모두보기
Evolus Inc 주식(EOLS)의 최신 뉴스
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Evolus Strengthens Talent Strategy: 30,579 RSUs Granted to Key New Hires with 2025 Vesting - Stock Titan
Midday Stock Roundup: US Markets Closed for Good Friday - Orange County Business Journal
Evolus announces commercial launch of Evolysse - MSN
BTIG Initiates Coverage of Evolus (EOLS) with Buy Recommendation - Nasdaq
BTIG Initiates Evolus at Buy With $21 Price Target - marketscreener.com
Evolus initiated with a Buy at BTIG - TipRanks
BTIG Initiates Coverage on Evolus (EOLS) with Optimistic Outlook | EOLS Stock News - GuruFocus
Evolus Launches "Drop The F Word" To Redefine Aesthetic Injectables With Evolysse - Nasdaq
Evolus Announces Commercial Launch of Evolysse™ | EOLS Stock New - GuruFocus
Evolus Announces Commercial Launch of Evolysse™ - Yahoo Finance
Evolus Launches “Drop the F Word” Campaign in Advance of the Com - GuruFocus
Game-Changing Cold-X Technology: Evolus Revolutionizes Injectable Aesthetics with Natural Results - Stock Titan
H.C. Wainwright maintains Buy on Evolus stock with $27 target - Investing.com
H.C. Wainwright maintains Buy on Evolus stock with $27 target By Investing.com - Investing.com Canada
Evolus stock hits 52-week low at $9.22 amid market challenges - Investing.com Canada
Evolus stock hits 52-week low at $9.22 amid market challenges By Investing.com - Investing.com South Africa
Midday Stock Roundup: Evolus, ICU Medical down - Orange County Business Journal
Breaking Down Evolus: 8 Analysts Share Their Views - Benzinga
Investors Give Evolus, Inc. (NASDAQ:EOLS) Shares A 31% Hiding - simplywall.st
Evolus at Needham Conference: Strategic Launch of Evolisse By Investing.com - Investing.com Canada
Evolus at Needham Conference: Strategic Launch of Evolisse - Investing.com
Sandra Beaver: Evolus on Track to Hit $700M Revenue - Orange County Business Journal
Recent 11% pullback isn't enough to hurt long-term Evolus (NASDAQ:EOLS) shareholders, they're still up 170% over 5 years - simplywall.st
Evolus, Inc.: Navigating Financial Challenges Amidst Ongoing Losses and Market Uncertainty - MSN
Evolus CEO David Moatazedi sells $77,512 in stock By Investing.com - Investing.com India
Evolus CEO David Moatazedi sells $77,512 in stock - Investing.com Australia
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference - BioSpace
Evolus Inc (EOLS) Shares Down 4.54% on Mar 25 - GuruFocus
Evolus Leadership Reveals Growth Strategy at Major Healthcare Conference - Stock Titan
Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain - Yahoo Home
Evolus reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:17 pm EDT - MarketScreener
Evolus director David Moatazedi sells $1.37 million in stock By Investing.com - Investing.com Australia
Evolus Growth Continues: 14 New Employees Join as Company Strengthens Talent Pool - Stock Titan
Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference - Business Wire
Evolus executive Avelar Rui sells $369,867 in stock By Investing.com - Investing.com South Africa
Evolus CFO Sandra Beaver sells $119,242 in company stock By Investing.com - Investing.com South Africa
Evolus chief marketing officer sells $60,124 in common stock By Investing.com - Investing.com South Africa
Evolus CFO Sandra Beaver sells $119,242 in company stock - Investing.com
Evolus director David Moatazedi sells $1.37 million in stock - Investing.com India
Evolus chief marketing officer sells $60,124 in common stock - Investing.com
When the Price of (EOLS) Talks, People Listen - news.stocktradersdaily.com
Trade Alert: Independent Director Of Evolus Karah Parschauer Has Sold Stock - Simply Wall St
Evolus director Parschauer sells $167,465 in common stock By Investing.com - Investing.com India
Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting - Business Wire
Evolus Inc (EOLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.71%
자본화:
|
볼륨(24시간):